Listed

Relmada Therapeutics, Inc.: Form 10-Q for the period ended Sep 30, 2015

Filed with the SEC on Nov 6, 2015 and accepted by EDGAR at Nov 6, 2015, 16:50 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2015-09-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Research and development3 months2015-07-01 to 2015-09-30$2.9mus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2015-07-01 to 2015-09-30−$4.6mus-gaap:OperatingIncomeLoss
Interest expense3 months2015-07-01 to 2015-09-30$1.6kus-gaap:InterestExpense
Net income3 months2015-07-01 to 2015-09-30$4.7mus-gaap:NetIncomeLoss
Diluted EPS3 months2015-07-01 to 2015-09-30$0.36us-gaap:EarningsPerShareDiluted
Basic EPS3 months2015-07-01 to 2015-09-30$0.43us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2015-07-01 to 2015-09-3012,937,385 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow3 months2015-07-01 to 2015-09-30−$3.2mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure3 months2015-07-01 to 2015-09-30$1.3kus-gaap:PaymentsToAcquireProductiveAssets
Cash and equivalentsAt period end2015-09-30$19.2mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2015-09-30$20.1mus-gaap:AssetsCurrent
Total assetsAt period end2015-09-30$20.5mus-gaap:Assets
Current liabilitiesAt period end2015-09-30$6.6mus-gaap:LiabilitiesCurrent
Shareholders' equityAt period end2015-09-30$13.8mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001213900-15-008265. Last ingested by Listed: Nov 13, 2026, 15:42 ET. Listed shows no prices and gives no investment advice.